Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection

AIDS

Volumn 14, Issue 18, 2000, Pages 2805-2812

  Yerly, Sabine ^a   Perneger, Thomas V ^a   Vora, Samir ^a   Hirschel, Bernard ^a   Perrin, Luc ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiretroviral therapy; Lymph nodes; Primary HIV infection; Reservoir; Viral decay

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DNA DEGRADATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 0034526101     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200012220-00001     Document Type: Article

References (27)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
4. HIV-1 dynamics in vivo: Virion clearance rale, infected cell lifespan, and viral generation time
5. Detection of low HIV-1 RNA levels in plasmas
6. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
7. Time of initiation of antiretroviral therapy: Impact on HIV-1 viremia
8. Presence of an inducible HIV-latent reservoir during highly active antiretroviral therapy
9. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
10. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
11. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
12. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
13. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 Infection: Results of the ANRS 053 trial
14. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
15. Viral burden in lymph nodes and blood of patients with primary HIV-1 infection on bitherapy
16. Viral suppression and CD4-cell recovery in patients with primary HIV-1 infection treated with HAART
17. Cell-associated HIV-1 RNA in blood as indicator of viral load in lymph nodes
18. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
19. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4
20. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
21. In vivo estimates of division and death rates of human T lymphocytes
22. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy
23. Evolution of envelope sequences of HIV-1 in cellular reservoirs in the setting of potent antiviral therapy
24. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia
25. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy
26. The prospect for new agents in the management of treatment failure
27. ABT-37B/ritonavir in antiretrovirnal-naive HIV+ patients: 72 Weeks